Page 53 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10(6):931-944.
16. Van Kuilenburg ABP, Dobritzsch D, Meinsma R, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein
structure. Biochem J. 2002;364(1):157-163.
17. EMA. European Medicines Agency. Xeloda (capecitabine): EPAR, product information. 2015; 3
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000316/
human_med_001157.jsp&mid=WC0b01ac058001d124. Accessed 29 July 2015.
18. FDA. U.S. Food and Drug Administration. Pharmacogenomic information capecitabine/
fluorouracil 2015; www.fda.gov. Accessed 29 July 2015.
19. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium
guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin
Pharmacol Ther. 2013;94(6):640-645.
20. Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte--an update of
guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
21. KNMP. Pharmacogenetics Working Group of the Royal Dutch Society for the Advancement of
Pharmacy. [Background information on DPD pharmacogenetics]. 2014; http://www.knmp.nl/ downloads/g-standaard/farmacogenetica/Algemene-achtergrondtekst-Farmacogenetica-2013- Dihydropyrimidine-Dehydrogenase.pdf. Accessed 29 July 2015.
22. Vreken P, VanKuilenburg ABP, Meinsma R, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645-654.
23. McLeod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics. 1998;8(6):455-459.
24. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12).
25. van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 2001;7(5):1149-1153.
26. van Kuilenburg AB, Vreken P, Beex LV, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer. 1997;33(13):2258-2264.
27. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958-1968.
28. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-4712.
29. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8699-8705.
30. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res. 2002;8(3):768-774.
DPYD gene activity score
51